Skip to main content

Advertisement

Figure 2 | Journal of Translational Medicine

Figure 2

From: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells

Figure 2

Enhanced BiAb mediated cytotoxicity in ipilimumab supplemented ATC of healthy donors. (a) T cells in PBMC derived from healthy donors were expanded with 0 (control) or 50 μg/mL of ipilimumab, and ATC were harvested, armed and tested for BiAb-mediated tumor specific cytotoxicity. EGFRBi armed ATC and COLO356/FG were co-cultured for 18 hours at E:T ratios of 25:1 (n = 9) and 12.5:1 (n = 7), and difference in the specific cytotoxicity was measured by 51Cr release assay ( left ). Cytotoxicity of EGFRBi armed ATC in the ipilimumab group was normalized to the control group to calculate the percent increase ( right ). (b) CD20Bi armed ATC and Daudi were co-cultured for 4 hours at E:T ratios of 25:1 (n = 11) and 12.5 (n = 8), and specific cytotoxicity was measured by 51Cr release assay ( left ). Cytotoxicity of CD20Bi armed ATC in the ipilimumab group was normalized to the control group to calculate the percent increase ( right ). Each bar represents a mean ± SE for ≥ 7 samples. The bar within each box shows a median while + symbol represents a mean for each data set. For each set of data, a paired two-tailed t test was performed.

Back to article page